Security Snapshot

Mineralys Therapeutics, Inc. - COMMON STOCK (MLYS) Institutional Ownership

CUSIP: 603170101

13F Institutional Holders and Ownership History from Q1 2023 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

157

Shares (Excl. Options)

79.23MFull value: 79,232,575 · shares · 30 Sep 2026

Price

$25.13

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.02%
Share change
-1,836,829
Value change
-$47,781,260
Number of holders
157
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
87,484,107
SEC-reported price per share
$23.72
Insider filing price
$23.72
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • MLYS - Mineralys Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 603170101.
  • 157 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 224 to 157 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.69BFull value: $2,688,746,355 · USD · 30 Jun 2026
    to
    $1.98BFull value: $1,978,752,867 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 157 institutions filings for Q3 2026.

Open SEC evidence

Security key

603170101

13F reference period

Q3 2026

13F holders

157

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
MLYS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Catalys Pacific Fund, LP 10% -24% $267,051,367 -$32,576,328 8,002,738 -11% Catalys Pacific Fund, LP 31 Dec 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $104,939,988 +$20,308,933 7,796,433 +24% RA Capital Management, L.P. 04 Sep 2025
Samsara BioCapital, L.P. 8.2% -10% $85,419,771 +$8,209,106 6,346,194 +11% Srinivas Akkaraju 04 Sep 2025
FMR LLC 5.1% -20% $123,544,181 -$15,390,656 4,461,689 -11% FMR LLC 30 Jun 2026
BlackRock, Inc. 5.2% $149,286,258 4,113,657 BlackRock, Inc. 31 Dec 2025
Andera Partners 4.2% $39,747,075 2,765,976 Andera Partners 30 Jun 2025
ADAMS STREET PARTNERS LLC 2.3% $15,320,183 1,129,807 Adams Street Partners, LLC 31 Dec 2024
As of 30 Sep 2026, 157 institutional investors reported holding
79.23MFull value: 79,232,575 · shares · 30 Sep 2026
shares of Mineralys Therapeutics, Inc. - COMMON STOCK (MLYS). This represents 91% of the company’s total
87.48MFull value: 87,484,107 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
67%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Catalys Pacific, LLC 8.9% 7,799,518 93% $196,001,887
RA CAPITAL MANAGEMENT, L.P. 8.8% 7,692,750 1.9% $193,318,808
SAMSARA BIOCAPITAL, LLC 6.7% 5,871,018 14% $147,538,682
DEERFIELD MANAGEMENT COMPANY, L.P. 4.5% 3,958,000 1.5% $99,464,540
VANGUARD CAPITAL MANAGEMENT LLC 3.4% 2,974,139 0% $74,740,113
STATE STREET CORP 3.3% 2,878,520 0% $72,337,208
Capital World Investors 2.9% 2,571,132 0.01% $64,612,547
Laurion Capital Management LP 2.8% 2,481,698 4.7% $62,365,071
ARMISTICE CAPITAL, LLC 2% 1,768,000 1.5% $44,429,840
GEODE CAPITAL MANAGEMENT, LLC 1.9% 1,684,708 0% $42,345,039
ANDERA PARTNERS 1.8% 1,591,917 23% $40,004,874
SR ONE CAPITAL MANAGEMENT, LP 1.8% 1,563,966 3.4% $39,302,466
ORBIMED ADVISORS LLC 1.7% 1,454,572 0.67% $36,553,394
Polar Capital Holdings Plc 1.6% 1,416,498 0.1% $35,596,595
Pictet Asset Management Holding SA 1.6% 1,376,686 0.03% $34,596,119
SPHERA FUNDS MANAGEMENT LTD. 1.5% 1,321,861 5% $33,218,367
BANK OF AMERICA CORP /DE/ 1.5% 1,307,700 0% $32,862,502
Point72 Asset Management, L.P. 1.5% 1,269,350 0.05% $31,898,766
Invesco Ltd. 1.3% 1,160,445 0% $29,161,982
Ghisallo Capital Management LLC 1.3% 1,125,000 0.54% $28,271,250
MONTANOVA CAPITAL, LLC 1.3% 1,100,974 0.76% $27,667,477
ALLIANCEBERNSTEIN L.P. 1.2% 1,088,911 0.01% $27,364,333
Troluce Capital Advisors LLC 1.2% 1,064,300 3.7% $26,745,859
Woodline Partners LP 1.1% 969,389 0.07% $24,360,746
Aberdeen Group plc 1.1% 932,358 0.03% $23,430,157

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
15
Headline period
Q3 2026
Rows shown
1-15 of 15
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 79,232,575 $1,978,752,867 -$47,781,260 $25.13 157
2026 Q2 99,652,122 $2,688,746,355 +$250,801,521 $26.98 224
2026 Q1 90,334,946 $2,455,300,033 -$6,322,554 $27.09 214
2025 Q4 88,390,661 $3,207,524,350 +$270,032,812 $36.29 223
2025 Q3 79,306,949 $3,007,317,130 +$505,416,563 $37.92 191
2025 Q2 65,687,280 $888,767,559 +$52,640,107 $13.53 164
2025 Q1 61,178,854 $971,385,613 +$245,430,113 $15.88 148
2024 Q4 46,486,259 $572,248,542 +$24,847,746 $12.31 108
2024 Q3 44,382,325 $540,052,185 +$2,379,010 $12.11 105
2024 Q2 44,151,028 $516,569,023 +$24,151,320 $11.70 93
2024 Q1 41,871,642 $540,562,541 +$93,970,804 $12.91 91
2023 Q4 34,713,391 $298,534,855 -$5,432,193 $8.60 87
2023 Q3 26,512,068 $252,135,025 -$9,247,223 $9.51 77
2023 Q2 25,186,898 $429,224,695 +$10,759,767 $17.05 68
2023 Q1 24,614,198 $385,431,208 +$385,431,208 $15.66 66
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .